Harvard Bioscience Net Income/Loss 2010-2024 | HBIO
Harvard Bioscience net income/loss from 2010 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
| Harvard Bioscience Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2024 | $-12 |
| 2023 | $-3 |
| 2022 | $-10 |
| 2021 | $0 |
| 2020 | $-8 |
| 2019 | $-5 |
| 2018 | $-3 |
| 2017 | $-1 |
| 2016 | $-4 |
| 2015 | $-19 |
| 2014 | $2 |
| 2013 | $-2 |
| 2012 | $2 |
| 2011 | $4 |
| 2010 | $19 |
| 2009 | $7 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Computer and Technology | Scientific Instruments Manufacturing | $0.015B | $0.094B |
| HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bruker (BRKR) | United States | $5.687B | 15.97 |
| Kewaunee Scientific (KEQU) | United States | $0.107B | 7.49 |